MCID: TTN003
MIFTS: 64

Tetanus

Categories: Bone diseases, Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tetanus

MalaCards integrated aliases for Tetanus:

Name: Tetanus 12 74 52 58 54 42 43 15 17 71
Lockjaw 52 3
Infection Due to Clostridium Tetani 12
Clostridial Tetanus 12

Characteristics:

Orphanet epidemiological data:

58
tetanus
Prevalence: <1/1000000 (France),<1/1000000 (Europe);

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11338
ICD9CM 34 037
MeSH 43 D013742
NCIt 49 C85185
SNOMED-CT 67 76902006
ICD10 32 A35
MESH via Orphanet 44 D013742
ICD10 via Orphanet 33 A33 A34 A35
UMLS via Orphanet 72 C0039614
Orphanet 58 ORPHA3299
UMLS 71 C0039614

Summaries for Tetanus

MedlinePlus : 42 Tetanus is a serious illness caused by Clostridium bacteria. The bacteria live in soil, saliva, dust, and manure. The bacteria can enter the body through a deep cut, like those you might get from stepping on a nail, or through a burn. The infection causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw. This makes it impossible to open your mouth or swallow. Tetanus is a medical emergency. You need to get treatment in a hospital. A vaccine can prevent tetanus. It is given as a part of routine childhood immunization. Adults should get a tetanus shot, or booster, every 10 years. If you get a bad cut or burn, see your doctor - you may need a booster. Immediate and proper wound care can prevent tetanus infection.

MalaCards based summary : Tetanus, also known as lockjaw, is related to diphtheria and poliomyelitis, and has symptoms including fever and pruritus. An important gene associated with Tetanus is VAMP2 (Vesicle Associated Membrane Protein 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Natalizumab and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and skeletal muscle, and related phenotypes are tremor and dysphagia

Disease Ontology : 12 A primary bacterial infectious disease that results in prolonged contraction of skeletal muscle fibers, has material basis in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli.

CDC : 3 Tetanus is different from other vaccine-preventable diseases because it does not spread from person to person. The bacteria are usually found in soil, dust, and manure and enter the body through breaks in the skin - usually cuts or puncture wounds caused by contaminated objects. Today, tetanus is uncommon in the United States, with an average of about 30 reported cases each year. Nearly all cases of tetanus are among people who did not get all the recommended tetanus vaccinations. This includes people who have never received a tetanus vaccine and adults who don't stay up to date on their 10-year booster shots.

Wikipedia : 74 Tetanus, also known as lockjaw, is a bacterial infection characterized by muscle spasms. In the most... more...

Related Diseases for Tetanus

Diseases related to Tetanus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 766)
# Related Disease Score Top Affiliating Genes
1 diphtheria 33.3 IL5 IL4 IL2RA IL2 IL13 IFNG
2 poliomyelitis 32.3 IL4 IL10 IFNG CD40LG
3 measles 31.8 IL2RA IL2 IFNG CD40LG
4 typhoid fever 31.7 LTA IFNG CD40LG
5 foodborne botulism 31.7 VAMP2 SNAP25 NSF
6 mumps 31.5 IL2RA IL2 IL10 IFNG CD40LG
7 rubella 31.3 IL5 IL4 IL2RA IL2 IL10 IFNG
8 smallpox 31.3 IL4 IL2 IFNG
9 hepatitis a 31.3 IL4 IL2 IL10 IFNG
10 allergic hypersensitivity disease 31.2 IL5 IL4 IL2 IL13 IL10 IFNG
11 neuritis 31.1 IL4 IL10 IFNG
12 otitis media 31.1 IL5 IL4 IL10 IFNG CD79A CD40LG
13 graft-versus-host disease 31.1 IL2 IL10 IFNG
14 myelitis 31.1 IL10 CD40LG CD27
15 respiratory failure 31.1 LTA IL5 IL13 IL10
16 leprosy 3 31.0 IL5 IL4 IL2 IL10 IFNG CD40LG
17 chickenpox 31.0 IL4 IL2 IL10 IFNG CD40LG CD27
18 lepromatous leprosy 31.0 IL4 IL2 IL10 IFNG
19 cytokine deficiency 31.0 IL5 IL13
20 erythema multiforme 31.0 IL5 IL4 IL2 IFNG
21 combined t cell and b cell immunodeficiency 31.0 IL4 IL2 IL10 CD40LG
22 peripheral nervous system disease 30.9 IL4 IL2 IL10 IFNG CD40LG
23 purpura 30.9 IL4 IL10 CD79A CD40LG
24 elephantiasis 30.9 IL5 IL4 IL10
25 myocarditis 30.9 IL4 IL2 IL10 IFNG CD40LG
26 onchocerciasis 30.9 IL5 IL4 IL2 IL13
27 meningitis 30.9 IL5 IL4 IL2 IL10 IFNG CD40LG
28 exanthem 30.9 IL2 IL10 CD40LG
29 herpes zoster 30.8 IL2 IL10 IFNG CD40LG
30 urticaria 30.8 IL5 IL4 IL13 CD40LG
31 yellow fever 30.8 IL5 IL4 CD40LG
32 ige responsiveness, atopic 30.8 IL5 IL4 IL13 IL10 IFNG
33 ileus 30.8 IL10 IFNG CD79A
34 viral hepatitis 30.7 IL4 IL2 IL10 IFNG CD40LG
35 myasthenia gravis 30.7 LTA IL4 IL2 IL10 IFNG
36 infant botulism 30.7 VAMP2 SNAP25 NSF
37 demyelinating disease 30.7 IL4 IL2 IL10 IFNG CD40LG
38 thrombocytopenia 30.7 IL4 IL2 IL10 IFNG CD79A CD40LG
39 dermatitis 30.7 IL5 IL4 IL2 IL13 IL10 IFNG
40 diarrhea 30.7 IL5 IL2 IL10 IFNG CD40LG
41 gastroenteritis 30.7 IL5 IL4 IL10 IFNG
42 cellulitis 30.7 IL5 IL10 CD40LG
43 schistosomiasis 30.7 IL5 IL4 IL2 IL13 IL10 IFNG
44 human immunodeficiency virus type 1 30.7 LTA IL2 IL10 IFNG CCR7
45 arthritis 30.6 LTA IL4 IL13 IL10 IFNG
46 pneumonia 30.6 IL5 IL4 IL2 IL13 IL10 IFNG
47 lichen planus 30.6 IL4 IL2 IL10 IFNG
48 wells syndrome 30.6 IL5 IL2RA IL2
49 chronic graft versus host disease 30.6 IL2RA IL10 IFNG CD79A
50 filarial elephantiasis 30.6 IL5 IL4 IL13 IL10

Graphical network of the top 20 diseases related to Tetanus:



Diseases related to Tetanus

Symptoms & Phenotypes for Tetanus

Human phenotypes related to Tetanus:

58 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 tremor 58 Occasional (29-5%)
2 dysphagia 58 Very frequent (99-80%)
3 hypertension 58 Occasional (29-5%)
4 bowel incontinence 58 Occasional (29-5%)
5 hypertonia 58 Frequent (79-30%)
6 fever 58 Frequent (79-30%)
7 cranial nerve paralysis 58 Occasional (29-5%)
8 elevated serum creatine phosphokinase 58 Occasional (29-5%)
9 abdominal pain 58 Occasional (29-5%)
10 respiratory distress 58 Occasional (29-5%)
11 muscle stiffness 58 Very frequent (99-80%)
12 rigidity 58 Frequent (79-30%)
13 laryngospasm 58 Occasional (29-5%)
14 coma 58 Occasional (29-5%)
15 trismus 58 Very frequent (99-80%)
16 tachycardia 58 Frequent (79-30%)
17 tachypnea 58 Occasional (29-5%)
18 intermittent painful muscle spasms 58 Frequent (79-30%)
19 humoral immunodeficiency 58 Frequent (79-30%)
20 opisthotonus 58 Very frequent (99-80%)
21 risus sardonicus 58 Very frequent (99-80%)
22 localized skin lesion 58 Frequent (79-30%)
23 stiff neck 58 Frequent (79-30%)
24 bradycardia 58 Occasional (29-5%)
25 spasticity of pharyngeal muscles 58 Occasional (29-5%)
26 elevated urinary norepinephrine 58 Occasional (29-5%)
27 elevated urinary epinephrine 58 Occasional (29-5%)
28 autonomic bladder dysfunction 58 Occasional (29-5%)
29 abnormal autonomic nervous system physiology 58 Occasional (29-5%)
30 rigors 58 Occasional (29-5%)

UMLS symptoms related to Tetanus:


fever, pruritus

GenomeRNAi Phenotypes related to Tetanus according to GeneCards Suite gene sharing:

26 (show all 44)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.2 CCR7 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.2 IL10
3 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.2 IL10
4 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.2 CCR7 IL10 IL13 VAMP7
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.2 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.2 VAMP7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.2 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.2 VAMP7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.2 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.2 IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.2 VAMP7
12 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.2 CCR7 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.2 IL13
14 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.2 VAMP7
15 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.2 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.2 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.2 CCR7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.2 VAMP7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.2 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.2 VAMP7
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.2 IL13
22 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.2 VAMP7
23 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.2 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.2 IL13
25 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.2 VAMP7
26 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.2 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.2 VAMP7
28 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.2 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.2 IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.2 IL10
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.06 IL2RA
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-130 10.06 IL2RA
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.06 IL2RA
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.06 IL10 IL2RA NSF VAMP7
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.06 IL2RA
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.06 IL2RA
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.06 NSF
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.06 IL10 IL2RA
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.06 IL10
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.06 IL10
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.06 IL10
42 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.06 NSF
43 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CD40LG IL10 IL2 IL2RA LTA STX3
44 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CD27 CD40LG IL10 IL2 IL2RA LTA

MGI Mouse Phenotypes related to Tetanus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.34 CCR7 CD27 CD40LG CD79A IFNG IL10
2 homeostasis/metabolism MP:0005376 10.25 CCR7 CD40LG CD79A IFNG IL10 IL13
3 immune system MP:0005387 10.21 CCR7 CD27 CD40LG CD79A IFNG IL10
4 endocrine/exocrine gland MP:0005379 10.2 CCR7 CD40LG IFNG IL10 IL13 IL2
5 mortality/aging MP:0010768 10.13 CD40LG CD79A IFNG IL10 IL13 IL2
6 digestive/alimentary MP:0005381 10.08 CCR7 IFNG IL10 IL13 IL2 IL2RA
7 nervous system MP:0003631 9.93 CCR7 CD40LG CD79A IFNG IL10 IL13
8 liver/biliary system MP:0005370 9.92 CD79A IFNG IL10 IL2 IL4 IL5
9 no phenotypic analysis MP:0003012 9.61 CCR7 CD79A IFNG IL10 IL13 IL2
10 respiratory system MP:0005388 9.28 IFNG IL10 IL13 IL2 IL2RA IL4

Drugs & Therapeutics for Tetanus

Drugs for Tetanus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 311)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4 189261-10-7
2
Adalimumab Approved Phase 4 331731-18-1 16219006
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
5
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
6
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
7
Remifentanil Approved Phase 4 132875-61-7 60815
8
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
9
Desflurane Approved Phase 4 57041-67-5 42113
10
Sodium citrate Approved, Investigational Phase 4 68-04-2
11
Cisatracurium Approved Phase 4 96946-41-7
12
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
13
Etanercept Approved, Investigational Phase 4 185243-69-0
14
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
15
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
16
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
17
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
18
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
19
Lopinavir Approved Phase 4 192725-17-0 92727
20
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
21
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22
BCG vaccine Investigational Phase 4
23
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
24 Adjuvants, Immunologic Phase 4
25 Immunosuppressive Agents Phase 4
26 Interleukin 1 Receptor Antagonist Protein Phase 4
27 Gastrointestinal Agents Phase 4
28 Anesthetics Phase 4
29 Central Nervous System Depressants Phase 4
30 MF59 oil emulsion Phase 4
31 Anesthetics, Local Phase 4
32 Anti-Inflammatory Agents Phase 4
33 Neurotransmitter Agents Phase 4
34 Neuromuscular Agents Phase 4
35 Cholinergic Agents Phase 4
36 Analgesics, Opioid Phase 4
37 Anesthetics, General Phase 4
38 Adjuvants, Anesthesia Phase 4
39 Autonomic Agents Phase 4
40 Narcotics Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 Neuromuscular Nondepolarizing Agents Phase 4
43 Muscarinic Antagonists Phase 4
44 Anesthetics, Inhalation Phase 4
45 Cholinergic Antagonists Phase 4
46 Cholinesterase Inhibitors Phase 4
47 Neuromuscular Blocking Agents Phase 4
48
Glycopyrrolate Phase 4 596-51-0 3494
49 Citrate Phase 4
50 glutamine Phase 4

Interventional clinical trials:

(show top 50) (show all 585)
# Name Status NCT ID Phase Drugs
1 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
2 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
3 Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults Unknown status NCT00336115 Phase 4
4 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
5 Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Boostrix® or Placebo in Healthy Adults Unknown status NCT02555540 Phase 4
6 The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study Unknown status NCT02771782 Phase 4
7 Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose Completed NCT00347958 Phase 4
8 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
9 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
10 Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX® Completed NCT00319553 Phase 4
11 Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose Completed NCT00712959 Phase 4
12 Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) Completed NCT01137435 Phase 4
13 Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
14 Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age Completed NCT00601835 Phase 4
15 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
16 A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age Completed NCT01357720 Phase 4
17 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
18 Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
19 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
20 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
21 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
22 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
23 A Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Estimate the Effect of Anakinra (r-metHuIL-1ra) on Vaccine Antibody Response in Subjects With Rheumatoid Arthritis (RA) Completed NCT00111410 Phase 4 Anakinra (r-metHuIL-1ra)
24 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age Completed NCT00457249 Phase 4
25 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
26 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
27 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. Completed NCT00610168 Phase 4
28 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
29 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
30 Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
31 Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child Completed NCT01711645 Phase 4
32 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
33 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
34 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
35 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
36 Double Strategy to Induce and Expand the T Cell Repertoire by the Administration of Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4 HAART
37 Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
38 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
39 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
40 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA™ Given Concomitantly With PedvaxHIB™ and Infanrix™ in Healthy Children 15 Months of Age Completed NCT00289913 Phase 4
41 Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life. Completed NCT00392808 Phase 4
42 A Phase 4, Randomized, Open-label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan. Completed NCT01250756 Phase 4
43 A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot Completed NCT02783170 Phase 4
44 A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
45 A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
46 A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation Completed NCT01094171 Phase 4
47 A Phase 4, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Prevenar in Healthy Children in China Who Have Been Previously Immunized With a 4-dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 0887x-101518 Completed NCT01298544 Phase 4
48 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
49 Shortening of the Twitch Stabilization Period by Tetanic Stimulation in Acceleromyography in Children and Young Adults Completed NCT02552875 Phase 4
50 Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years Completed NCT02215863 Phase 4

Search NIH Clinical Center for Tetanus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorpromazine
Chlorpromazine hydrochloride
cyclobenzaprine
Cyclobenzaprine hydrochloride
Methocarbamol
Metocurine iodide
Orphenadrine
Orphenadrine Citrate
Orphenadrine Hydrochloride
Tetanus Antitoxin
TETANUS ANTITOXIN,EQUINE
Tetanus immune globulin
Tetanus immune globulin, human
tetanus toxoid vaccine, inactivated

Cochrane evidence based reviews: tetanus

Genetic Tests for Tetanus

Anatomical Context for Tetanus

MalaCards organs/tissues related to Tetanus:

40
T Cells, Testes, Skeletal Muscle, B Cells, Brain, Bone, Skin

Publications for Tetanus

Articles related to Tetanus:

(show top 50) (show all 22942)
# Title Authors PMID Year
1
Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten - United States, 2018-19 School Year. 61 42
31622283 2019
2
DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination. 61 42
31444785 2019
3
A pilot study of a novel, incentivised mHealth technology to monitor the vaccine supply chain in rural Zambia. 42
31448013 2019
4
In vitro cytokine responses to periodontal pathogens: generalized aggressive periodontitis is associated with increased IL-6 response to Porphyromonas gingivalis. 54 61
20500696 2010
5
Failure of highly active antiretroviral therapy in reconstituting immune response to Clostridium tetani vaccine in aged AIDS patients. 54 61
20224419 2010
6
CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function. 54 61
20194631 2010
7
[Conditional cell targeting and reversible synapse silencing to study neural circuits]. 54 61
20297730 2010
8
Association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients. 54 61
19744828 2010
9
Stimulation of anti-polio and anti-HSV IgA pre-plasma cell response in blood following parenteral immunization with tetanus-diphtheria vaccine. 54 61
20003921 2010
10
Transport of AMPA receptors during long-term potentiation is impaired in rats with hepatic encephalopathy. 54 61
19450629 2009
11
VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. 54 61
19910495 2009
12
Subcellular localization of the carbohydrate Lewis(x) adhesion structure in hippocampus cell cultures. 54 61
19576189 2009
13
T-cell reactivity during tapering of immunosuppression to low-dose monotherapy prednisolone in HLA-identical living-related renal transplant recipients. 54 61
19300195 2009
14
The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope. 54 61
19010547 2009
15
Role of HRB in clathrin-dependent endocytosis. 54 61
18819912 2008
16
Enhancement of human antigen-specific memory T-cell responses by interleukin-7 may improve accuracy in diagnosing tuberculosis. 54 61
18753334 2008
17
GLUT4 vesicle recruitment and fusion are differentially regulated by Rac, AS160, and Rab8A in muscle cells. 54 61
18650435 2008
18
The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. 54 61
18653385 2008
19
Transient silencing of synaptic transmitter release from specific neuronal types by recombinant tetanus toxin light chain fused to antibody variable region. 54 61
18775748 2008
20
Effect of HLA genotype or CTLA-4 polymorphism on cytokine response in healthy children. 54 61
18782261 2008
21
Peanut-specific B and T cell responses are correlated in peanut-allergic but not in non-allergic individuals. 54 61
18564333 2008
22
Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. 54 61
18511417 2008
23
Molecular basis for tetanus toxin coreceptor interactions. 54 61
18543947 2008
24
Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. 54 61
18422727 2008
25
A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action. 54 61
18341617 2008
26
Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. 54 61
18450120 2008
27
Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. 54 61
18337418 2008
28
Lysosomal cysteine and aspartic proteases are heterogeneously expressed and act redundantly to initiate human invariant chain degradation. 54 61
18292509 2008
29
Dynamics of intracellular oxygen in PC12 Cells upon stimulation of neurotransmission. 54 61
18086678 2008
30
Targeting the epithelial SNARE machinery by bacterial neurotoxins. 54 61
18369946 2008
31
An in vitro assay for detection of tetanus neurotoxin activity: using antibodies for recognizing the proteolytically generated cleavage product. 54 61
17826026 2007
32
Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination. 54 61
17850592 2007
33
Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. 54 61
17654744 2007
34
Effects of intravenous immunoglobulins on peripheral blood mononuclear cell activation in vitro. 54 61
17911484 2007
35
What is the function of neuronal AP-3? 54 61
17567262 2007
36
Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. 54 61
17613604 2007
37
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. 54 61
17544998 2007
38
v-SNARE cellubrevin is required for basolateral sorting of AP-1B-dependent cargo in polarized epithelial cells. 54 61
17485489 2007
39
Increased levels of fucosyltransferase IX and carbohydrate Lewis(x) adhesion determinant in human NT2N neurons. 54 61
17335083 2007
40
Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. 54 61
17182676 2007
41
Parental smoking impairs vaccine responses in children with atopic genotypes. 54 61
17291854 2007
42
Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. 54 61
17691381 2007
43
Distinct functions of neuronal synaptobrevin in developing and mature fly photoreceptors. 54 61
16967508 2006
44
Effects of probiotic supplementation for the first 6 months of life on allergen- and vaccine-specific immune responses. 54 61
17014429 2006
45
Bacterial extract (OM-89) specific and non specific immunomodulation in rheumatoid arthritis patients. 54 61
16891218 2006
46
Increased apoptosis of CD20+ IgA + B cells is the basis for IgA deficiency: the molecular mechanism for correction in vitro by IL-10 and CD40L. 54 61
16758339 2006
47
Reduced tetanus antibody titers in overweight children. 54 61
16698670 2006
48
Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. 54 61
16404742 2006
49
Fifteen year experience of intrathecal baclofen treatment in Japan. 54 61
17370766 2006
50
A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. 54 61
16369026 2006

Variations for Tetanus

Expression for Tetanus

Search GEO for disease gene expression data for Tetanus.

Pathways for Tetanus

Pathways related to Tetanus according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 VAMP3 STX3 SNAP25 SNAP23 LTA IL5
2
Show member pathways
13.83 LTA IL5 IL4 IL2RA IL2 IL13
3
Show member pathways
13.7 LTA IL5 IL4 IL2RA IL2 IL13
4
Show member pathways
13.54 LTA IL5 IL4 IL2RA IL2 IL13
5
Show member pathways
13.46 LTA IL5 IL4 IL2RA IL2 IL13
6
Show member pathways
13.36 STX3 LTA IL5 IL4 IL2RA IL2
7
Show member pathways
13.33 LTA IL5 IL4 IL2RA IL2 IL13
8 12.85 IL5 IL4 IL2RA IL2 IL13 IFNG
9
Show member pathways
12.85 LTA IL5 IL4 IL2RA IL2 IL13
10
Show member pathways
12.71 IL4 IL2RA IL2 IL10 IFNG CD79A
11
Show member pathways
12.67 IL5 IL4 IL2RA IL2 IL13 IL10
12
Show member pathways
12.65 IL5 IL4 IL2 IL10 IFNG CD40LG
13 12.61 IL4 IL2RA IL2 IL10 IFNG CD79A
14
Show member pathways
12.46 VAMP7 VAMP2 SNAP25 SNAP23 NSF
15
Show member pathways
12.43 IL5 IL2RA IL2 IL13
16
Show member pathways
12.37 LTA IL2RA IL2 IL10 CCR7
17
Show member pathways
12.34 IL5 IL4 IL2RA IL2 IL13 IL10
18
Show member pathways
12.33 IL5 IL4 IL13 IFNG
19
Show member pathways
12.29 LTA IL5 IL4 IL2RA IL2 IL13
20
Show member pathways
12.26 IL4 IL10 IFNG CD40LG
21 12.19 VAMP2 SNAP25 IL13 IL10
22
Show member pathways
12.08 LTA IL2 IL10 IFNG
23
Show member pathways
12.07 VAMP2 STX3 SNAP25 NSF
24
Show member pathways
12.05 IL5 IL2RA IL2 IL13
25
Show member pathways
12 IL4 IL2RA IL2 IFNG
26
Show member pathways
11.98 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
27 11.92 IL2RA IL2 IL10 IFNG
28 11.92 IL5 IL4 IL2RA IL2 IL10 IFNG
29 11.89 IL5 IL4 IL2 IL13 IFNG
30 11.79 IL4 IL2 IL13 IL10 IFNG
31
Show member pathways
11.76 LTA IL4 IL2RA IL2
32
Show member pathways
11.76 IL5 IL4 IL2RA IL2 IFNG CD40LG
33 11.75 IL2 IL10 IFNG
34 11.72 LTA IL5 IL4 IL10 CD40LG
35
Show member pathways
11.67 IL2 IFNG CD40LG
36 11.67 IL5 IL4 IL13
37
Show member pathways
11.65 IL2RA IL2 IFNG
38 11.59 IL10 CD40LG CD27
39 11.56 IL10 IFNG CD40LG
40 11.55 IL4 IL13 IL10
41 11.46 LTA IL5 IL4 IL2RA IL2 IL13
42
Show member pathways
11.44 VAMP2 SNAP25 NSF
43 11.4 IL5 IL4 IL13 IFNG
44 11.36 IL5 IL4 IL2RA IL2 IFNG CD40LG
45 11.36 IL5 IL4 IL2RA IL2 IL13 IL10
46 11.34 IL2RA IL2 IL13 IFNG
47 11.26 IL5 IL4 IL2 IL13 IL10 IFNG
48 11.06 LTA IL5 IL4 IL2 IL13 IL10
49 10.65 VAMP2 SNAP25
50 10.58 LTA IL5 IL4 IL2 IL13 IL10

GO Terms for Tetanus

Cellular components related to Tetanus according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.18 LTA IL5 IL4 IL2 IL13 IL10
2 plasma membrane GO:0005886 10.17 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
3 extracellular space GO:0005615 10.14 LTA IL5 IL4 IL2 IL13 IL10
4 cell surface GO:0009986 9.91 VAMP7 VAMP3 IL2RA CD40LG CD27 CCR7
5 synaptic vesicle GO:0008021 9.67 VAMP7 VAMP2 STX3 SNAP25
6 phagocytic vesicle membrane GO:0030670 9.65 VAMP7 VAMP3 SNAP23
7 clathrin-coated vesicle membrane GO:0030665 9.63 VAMP7 VAMP3 VAMP2
8 neuron projection GO:0043005 9.63 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
9 secretory granule GO:0030141 9.56 VAMP7 VAMP3 VAMP2 STX3
10 specific granule GO:0042581 9.55 STX3 SNAP23
11 zymogen granule membrane GO:0042589 9.51 VAMP2 STX3
12 azurophil granule GO:0042582 9.49 STX3 SNAP23
13 external side of plasma membrane GO:0009897 9.43 IL2RA IL13 CD79A CD40LG CD27 CCR7
14 synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex GO:0070032 9.4 VAMP2 SNAP25
15 SNARE complex GO:0031201 9.1 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23

Biological processes related to Tetanus according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.09 IL4 IL2 IL10 CD40LG CD27
2 inflammatory response GO:0006954 10.07 IL5 IL13 IL10 CD40LG CCR7
3 vesicle-mediated transport GO:0016192 9.99 VAMP7 VAMP3 VAMP2 STX3 NSF
4 cell surface receptor signaling pathway GO:0007166 9.98 IL2RA IFNG CD79A CD27
5 response to lipopolysaccharide GO:0032496 9.96 LTA IL13 IL10 CCR7
6 B cell differentiation GO:0030183 9.86 IL4 IL10 CD79A CD40LG
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IL4 IL2 IL13 IFNG
8 positive regulation of T cell proliferation GO:0042102 9.83 IL4 IL2RA IL2 CD40LG
9 negative regulation of endothelial cell apoptotic process GO:2000352 9.8 IL4 IL13 IL10
10 B cell proliferation GO:0042100 9.79 IL10 CD79A CD40LG
11 calcium ion regulated exocytosis GO:0017156 9.76 VAMP7 VAMP3 VAMP2
12 long-term synaptic potentiation GO:0060291 9.76 VAMP2 STX3 SNAP25 MPP2
13 positive regulation of interleukin-12 production GO:0032735 9.75 IFNG CD40LG CCR7
14 post-Golgi vesicle-mediated transport GO:0006892 9.74 VAMP7 VAMP2 SNAP23
15 positive regulation of B cell proliferation GO:0030890 9.73 IL5 IL4 IL2 IL13
16 regulation of regulatory T cell differentiation GO:0045589 9.71 IL2RA IL2 IFNG
17 membrane fusion GO:0061025 9.71 VAMP3 VAMP2 STX3 SNAP23
18 cytokine-mediated signaling pathway GO:0019221 9.7 STX3 IL5 IL4 IL2RA IL2 IL13
19 interleukin-2-mediated signaling pathway GO:0038110 9.69 IL2RA IL2
20 synaptic vesicle fusion to presynaptic active zone membrane GO:0031629 9.69 STX3 SNAP25 SNAP23
21 synaptic vesicle docking GO:0016081 9.68 STX3 SNAP25
22 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 IL4 IL2
23 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.68 IL4 IL10
24 SNARE complex assembly GO:0035493 9.67 VAMP7 VAMP3
25 negative regulation of lymphocyte proliferation GO:0050672 9.67 IL2RA IL2
26 positive regulation of immunoglobulin secretion GO:0051024 9.67 VAMP3 IL5 IL2
27 Golgi to plasma membrane protein transport GO:0043001 9.67 VAMP7 VAMP3 VAMP2 NSF
28 natural killer cell degranulation GO:0043320 9.66 VAMP7 VAMP2
29 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
30 exocytic insertion of neurotransmitter receptor to postsynaptic membrane GO:0098967 9.65 STX3 SNAP25
31 type 2 immune response GO:0042092 9.65 IL4 IL10
32 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL4 IL10 IFNG
33 positive regulation of cellular respiration GO:1901857 9.64 IL4 IFNG
34 mucus secretion GO:0070254 9.64 VAMP3 VAMP2
35 regulation of isotype switching GO:0045191 9.63 IL4 IL10
36 eosinophil degranulation GO:0043308 9.63 VAMP7 VAMP2
37 vesicle fusion GO:0006906 9.62 VAMP7 STX3 SNAP25 SNAP23
38 negative regulation of complement-dependent cytotoxicity GO:1903660 9.61 IL4 IL13
39 regulation of histamine secretion by mast cell GO:1903593 9.61 VAMP3 VAMP2
40 regulation of T cell homeostatic proliferation GO:0046013 9.6 IL2RA IL2
41 positive regulation of T cell differentiation GO:0045582 9.56 IL4 IL2RA IL2 CD27
42 exocytosis GO:0006887 9.5 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
43 immune response GO:0006955 9.32 LTA IL5 IL4 IL2RA IL2 IL13

Molecular functions related to Tetanus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
2 growth factor activity GO:0008083 9.71 IL5 IL4 IL2 IL10
3 SNARE binding GO:0000149 9.62 VAMP7 VAMP2 STX3 NSF
4 SNAP receptor activity GO:0005484 9.56 VAMP7 STX3 SNAP25 SNAP23
5 syntaxin-1 binding GO:0017075 9.46 VAMP3 VAMP2 SNAP25 NSF
6 syntaxin binding GO:0019905 9.35 VAMP7 VAMP2 SNAP25 SNAP23 NSF
7 cytokine activity GO:0005125 9.23 LTA IL5 IL4 IL2 IL13 IL10

Sources for Tetanus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....